LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

Jana Samarin / Piotr Fabrowski / Roman Kurilov / Hana Nuskova / Johanna Hummel-Eisenbeiss / Hannelore Pink / Nan Li / Vivienn Weru / Hamed Alborzinia / Umut Yildiz / Laura Grob / Minerva Taubert / Marie Czech / Michael Morgen / Christina Brandstädter / Katja Becker / Lianghao Mao / Ashok Kumar Jayavelu / Angela Goncalves /
Ulrike Uhrig / Jeanette Seiler / Yanhong Lyu / Sven Diederichs / Ursula Klingmüller / Martina Muckenthaler / Annette Kopp-Schneider / Aurelio Teleman / Aubry K. Miller / Nikolas Gunkel

Redox Biology, Vol 62, Iss , Pp 102639- (2023)

2023  

Abstract: Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to ... ...

Abstract Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of “antioxidant-capacity” biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive cells, rendering them susceptible to multiple redox-targeting and ferroptosis-inducing drugs. Contrary to expectation, constitutively low ACB expression was not associated with an increased steady state level of reactive oxygen species (ROS) but a high level of nitric oxide, which is required to sustain high replication rates. Using ACBs, we identified cancer entities with a high percentage of patients with favorable ACB expression pattern, making it likely that more responders to ROS-inducing drugs could be stratified for clinical trials.
Keywords Biomarker ; TXNRD1 inhibitor ; Nitric oxide ; Ferroptosis ; NRF2 ; Medicine (General) ; R5-920 ; Biology (General) ; QH301-705.5
Subject code 610
Language English
Publishing date 2023-06-01T00:00:00Z
Publisher Elsevier
Document type Article ; Online
Database BASE - Bielefeld Academic Search Engine (life sciences selection)

More links

Kategorien

To top